Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Filings indexed 738 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Regulatory Filings
2026-05-05 English
10-Q - Spyre Therapeutics, Inc. (0001636282) (Filer)
Interim / Quarterly Report
2026-05-05 English
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Regulatory Filings
2026-04-16 English
424B5 - Spyre Therapeutics, Inc. (0001636282) (Filer)
Prospectus
2026-04-13 English
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Regulatory Filings
2026-04-13 English
8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)
Regulatory Filings
2026-04-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.